Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer

• Status: Active, not recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Docetaxel; Nivolumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Disease progression experienced during or after one prior platinum containing doublet chemotherapy

• Stage IIIb/IV or recurrent disease

• Male and Female ≥ 18 years of age

• Measurable disease per RECIST 1.1

• Performance Status ≤ 1

Exclusion Criteria:

• History of Carcinomatous meningitis

• Active Central nervous system (CNS) metastases

• History of auto immune diseases

• Prior treatment with Docetaxel

• Prior treatment with ipilimumab or any drug targeting T-Cell costimulation or checkpoint pathways